Time is running out to make your tax-deductible 2016 gift to OCRFA. We need your help. Over 22,000 women will be diagnosed with ovarian cancer in 2017. Over 200,000 women are currently living with ovarian cancer. Your support will make a big difference in the lives of these women and their families. Ovarian cancer is … Continued
Every year, 22,000 women are newly diagnosed with ovarian cancer. As OCRFA strives toward a cure and better treatments through research, we also provide patients and survivors with the care they need through our support and education programs. Now in 29 sites across the country, our Woman to Woman program has impacted over 400 women, … Continued
(Dec. 21, 2016) Research published recently in Cancer Discovery suggests that cells in the fallopian tube previously thought to be precursors to high grade serous ovarian cancer may sometimes be cells that have metastasized and implanted into the fallopian tube. The research was conducted by a team at the University of Chicago under the guidance … Continued
(Dec. 19, 2016) The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as … Continued
As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level. In 2016, with the help of committed Advocate Leaders, Grassroots Advocates, Research Advocates and action alert supporters, OCRFA was able to: We’ve made great strides in ensuring that ovarian … Continued
OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and prevent the disease, and discover better treatments. In 2016, our grantees made significant advances in the fight against ovarian cancer, including: Progress is being made … Continued
Tickets are now available for the 2017 Turn Up the Heat! Gala in Washington DC. Turn Up the Heat features food from the top female chefs in DC and the surrounding area! Join us on February 22nd for a night full of delicious food and great company. Get your tickets at www.turnuptheheatgala.org
The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker. At the time Ann was diagnosed with ovarian cancer in 1996, she was already a political powerhouse, having early involvement with organizations like the National Women’s Political Caucus and Emily’s List. We are now accepting applications for the Fall 2017 Fellowship.
(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone. The approval is based on two large Phase III … Continued
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing recurrent ovarian cancer, discussing the goals of treatment during recurrence, typical courses of treatment, and advice on how to approach making decisions about treatment during … Continued
OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. Ronald Alvarez, MD, MBA, of Vanderbilt University Medical Center, Deborah Armstrong, MD, of Johns Hopkins School of Medicine, Robert Coleman, MD, of M.D. Anderson Cancer … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side … Continued
Get email updates about research news, action alerts, and ways to join the fight.
